Allan C. Golston Sells 3,273 Shares of Stryker Co. (NYSE:SYK) Stock

Stryker Co. (NYSE:SYKGet Free Report) Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Stryker Stock Up 0.9 %

Stryker stock opened at $342.72 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The business has a 50 day simple moving average of $305.85 and a 200-day simple moving average of $288.70. The stock has a market capitalization of $130.20 billion, a PE ratio of 41.54, a price-to-earnings-growth ratio of 2.79 and a beta of 0.90. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $346.59.

Stryker (NYSE:SYKGet Free Report) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, analysts anticipate that Stryker Co. will post 11.87 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th were issued a $0.80 dividend. The ex-dividend date was Thursday, December 28th. This represents a $3.20 dividend on an annualized basis and a yield of 0.93%. This is a positive change from Stryker’s previous quarterly dividend of $0.75. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Institutional Investors Weigh In On Stryker

A number of large investors have recently modified their holdings of SYK. Freedom Wealth Alliance LLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. Quarry LP purchased a new stake in shares of Stryker in the first quarter valued at about $27,000. Rise Advisors LLC increased its position in Stryker by 692.9% during the third quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Finally, Rogco LP acquired a new position in Stryker in the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 76.24% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on SYK. Citigroup increased their price objective on shares of Stryker from $340.00 to $362.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. UBS Group raised their target price on Stryker from $289.00 to $297.00 and gave the stock a “neutral” rating in a research note on Thursday, November 9th. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a research note on Wednesday, January 31st. Morgan Stanley raised their price objective on Stryker from $300.00 to $320.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. Finally, Wells Fargo & Company upped their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $331.52.

Read Our Latest Report on SYK

Stryker Company Profile

(Get Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with's FREE daily email newsletter.